News

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.

The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.

This new research indicates that while there are ongoing trials seeking to define which individuals with subsegmental PE may be surveilled, greater uptake of newer surveillance actions may necessitate more than passive diffusion.

CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.

In this Q&A interview with Dr. Rieder, he describes the biggest takeaways from his panel discussion on the mental health needs of dermatology patients.

Enhancing access to biosimilars in the US involves multiple key factors, including active participation from payers, providers, and the healthcare community to incentivize the utilization of biosimilars.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

The FDA has updated its list of UV wands, used to disinfect surfaces, to avoid due to potentially harmful levels of radiation exposure.

Several key initiatives designed to streamline and enhance the efficiency of biosimilar development in the US market are underway, underscoring the timeliness of the Biosimilars Forum's recent report.

This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.

Granted to Ipsen, the breakthrough treatment reduces new, abnormal bone growth in people living with the ultra-rare bone disease.

A new study revealed differences in the diagnostic performance of the FIB-4 and NFS, indicating that conventional NFS cutoff values may be unsuitable for screening lean NAFLD patients.

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th anniversary celebration.

In his latest recorded interview, Dr. Eichenfield described the use of VP-102, or cantharidin 0.7%, for molluscum contagiosum.

Treatment with follitropin alfa resulted in a higher proportion of patients with good quality embryos and higher pregnancy rates when compared with the biosimilar group.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

Juliana Reed, MS, discusses the recent publication of a peer-reviewed report by the Biosimilars Forum on the future trajectory of biosimilar development and its applications.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

This new data highlights the lack of reliability with regard to medical information disseminated on social media platforms, and the frequency at which such information is observed.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

This new data from China showed that both the duration of mask-wearing and greater use of facial cleansing may result in skin deterioration, though moisturizing products were found to have more positive effects.

Comparable efficacy, including of BCVA, CST, and fluid status between SB15 and reference aflibercept, was maintained up to Week 56 in nAMD eyes.

The pioneer in social anxiety disorder discusses how the investigative nasal spay may alter the trajectory of patients' conditions.

As some people are more likely to develop rheumatoid arthritis, recognizing this group leads to earlier diagnosis and treatment. Test your knowledge with this quiz.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

This analysis demonstrated the efficacy of topical azelaic acid, though further randomized control trial evidence may be needed for an evaluation of the treatment on skin aging.